Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

BACKGROUND: Although low-grade serous ovarian cancer (LGSC) is rare, case-fatality rates are high as most patients present with advanced disease and current cytotoxic therapies are not overly effective. Recognizing that these cancers may be driven by MAPK pathway activation, MEK inhibitors (MEKi) ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez, Marta Llaurado, Dawson, Amy, Hoenisch, Joshua, Kim, Hannah, Bamford, Sylvia, Salamanca, Clara, DiMattia, Gabriel, Shepherd, Trevor, Cremona, Mattia, Hennessy, Bryan, Anderson, Shawn, Volik, Stanislav, Collins, Colin C., Huntsman, David G., Carey, Mark S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325847/
https://www.ncbi.nlm.nih.gov/pubmed/30636931
http://dx.doi.org/10.1186/s12935-019-0725-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325847/
https://www.ncbi.nlm.nih.gov/pubmed/30636931
http://dx.doi.org/10.1186/s12935-019-0725-1

Ejemplares similares